Senseonics to Participate in the Guggenheim MedTech Disruptors Summit

GERMANTOWN, Md.–(BUSINESS WIRE)–Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology
company focused on the development and commercialization of a long-term,
implantable continuous glucose monitoring (CGM) system for people with
diabetes, today announced the company plans to participate in the
upcoming Guggenheim MedTech Disruptors Summit in New York, NY.

Management is scheduled to present Wednesday, May 29, 2019 at 10:00am
ET. Interested parties may access a live and recorded webcast of the
presentation on the “Investor Relations” section of the company’s
website at www.senseonics.com.

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the
design, development and commercialization of transformative glucose
monitoring products designed to help people with diabetes confidently
live their lives with ease. From its inception, Senseonics has been
advancing the integration of novel, fluorescence sensor technology with
smart wearable devices. The Eversense^® CGM System received
PMA approval from the FDA for up to 90 days of continuous use and is
available in the United States. The Eversense^® XL CGM System
received CE mark for up to 180 days of continuous use and is available
in Europe. For more information on Senseonics, please visit www.senseonics.com.

Contacts

Senseonics Investor Relations Contact:
Lynn Lewis or Philip
Taylor
Investor Relations
415-937-5406
Investors@senseonics.com